Search Results

HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX’s CAR-T cell therapy in patients with kappa-type myeloma.

Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-004) for the treatment of ovarian cancer.

The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous T-cell lymphoma (CTCL).

Monday’s failure to improve overall survival in breast cancer “further dents belief” in the companies’ Dato-DXd and “likely complicates regulatory discussions for approval of this indication,” Jefferies analyst Peter Welford wrote in a note to investors.

Peter MacCallum Cancer Centre, world leading cancer research, education and treatment center and Isotopia Molecular Imaging Limited (Isotopia), a global supplier of radioisotopes for targeted therapies, today announced they have signed a clinical research and supply agreement for the medical radioisotope no-carrier-added Terbium-161 (n.c.a. Tb-161).,

BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for high value, traditionally undruggable targets, today announced a research collaboration agreement with the Peter MacCallum Cancer Centre (Peter Mac), a world leading research, education, and treatment center in Melbourne, Australia.

Arialys Therapeutics today announced the appointment of Peter Flynn, Ph.D., as President and Chief Executive Officer.

SeeMedX, Inc. announced the appointment of Dr. Peter Ganz to its advisory board, effective immediately.

Epsilogen, a global leader in the development of immunoglobulin E antibodies to treat cancer, announces the appointments of Ashley Nagle as Chief Business Officer and Peter Finan, currently a Non-Executive Director, as Non-Executive Chairman.

Initial Therapeutics Inc. has appointed Peter DiLaura as President and Chief Executive Officer and a member of the company’s Board of Directors, effective immediately.